Amgen kept at neutral by Merrill

Merrill Lynch analyst Eric Ende maintained Amgen Inc. at a neutral rating following the Federal Circuit court's decision that Dynepo infringes Amgen's U.S. Patent No. 5,618,698 (a process for producing erythropoietin), and U.S. Patent No. 5,756,349 (covering cells to produce recombinant epo) and that the patents are valid. The analyst looks for a decision on the CERA case on Roche's motion to dismiss. This case involves the '698 and '349 patents that were upheld as valid and infringed by the Federal Circuit. Shares of the Thousand Oaks, Calif.-based biotechnology company were down $2.13, or 3.00%, at $68.79, on volume of 14,233,456 shares versus the three-month running average of 8,581,840 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.